ArticleLangmuir : the ACS journal of surfaces and colloids2025
Surface Modification of Poly(dimethylsiloxane) Blood Flow Chambers with a Poly(ethylene glycol) Conjugate and Factor XII Inhibitor.
Article in Langmuir : the ACS journal of surfaces and colloids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing the Hemocompatibility of 3D-Printable Silicone Elastomers for Artificial Lung Applications.Langmuir : the ACS journal of surfaces and colloids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study is focused on the application of a dual surface coating on poly(dimethylsiloxane) (PDMS) flow chambers, which aims to inhibit the contact activation pathway of coagulation. Polyethylene glycol (PEG) is a commonly used biocompatible molecule due to its hydrophilic nature and capacity to reduce protein adsorption. Corn trypsin inhibitor (CTI) is a selective inhibitor of Factor XII, which is the initial factor responsible for activating the intrinsic pathway of coagulation. By sequentially applying these two coatings to PDMS substrates, we expect the PEG-CTI coating to decrease blood clot formation and reduce fibrinogen deposition on surfaces compared to uncoated surfaces. Our results indicate that the PEG-CTI coating was successful in significantly reducing both cell adsorption and fibrinogen deposition to the surfaces of PDMS flow chambers. This study is a step toward applying PEG-CTI surface coatings to PDMS microfluidic artificial lungs, in which the surface interaction between the PDMS lungs and blood is a critical issue that must be mitigated to realize the full potential of this exciting therapeutic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.